• 2013 : First test to be combined with elastography

    Elasto-FibroTest 1 is the first diagnostic test for the liver that combines the results of the FibroTest-ActiTest with an elastography result, directly from your smartphone.

  • 2011 : First test to be combined with genetic analysis

    Launch of the HCV-GenoFibroTest 2 , which anticipates the response to interferon treatments for hepatitis C; in particular in combination with FibroTest and genotype IL28b.

  • 2005 : Launch of FibroMax

    FibroMax offers a complete diagnosis of the state of the liver with a single blood test:

    • FibroTest: evaluates hepatic fibrosis and cirrhosis
    • ActiTest: evaluates the level of necroinflammatory activity.
    • SteatoTest 3 : steatosis (fatty liver deposit) assessment
    • NashTest 4 : evaluates non-alcoholic steatohepatitis (inflammation of the liver due to metabolic causes)
    • AshTest 5 : evaluates alcoholic steatohepatitis (inflammation of the liver due to alcohol)
  • 2003 : Launch in the USA

    FibroTest becomes available in the United States, distributed by LabCorp, under the FibroSure brand.

    A few years later, BioPredictive tests were distributed by the major North American laboratories.

  • 2002 : The history of BioPredictive

    Founding of BioPredictive, head of R&D, business development and distribution of FibroTest-ActiTest

  • 2001 : Invention of FibroTest

    FibroTest 6 developed by the Hepatology Department team at La Pitié-Salpêtrière University Hospital, Paris, France. The first combination of blood markers that replaces liver biopsies when testing for hepatic fibrosis. Patents held by the Assistance Publique des Hôpitaux de Paris (APHP).

  • 1996 : METAVIR

    METAVIR 7 classification, which separates fibrosis and activity in the histological evaluation (the biopsy) of the seriousness of the liver disease.

  • 1994 : PGA Index

    The first test 8 for hepatic fibrosis combining the usual blood markers.

Our values


Innovation is part of BioPredictive's DNA.

This has been part of the company's routine since 2002:

  • With the medical revolution brought about by the first non-invasive diagnostic test for fibrosis/cirrhosis in 2002.
  • Innovation also applies to their scientific approach: the disruption of the liver biopsy 6 , new data analysis methodologies (METAVIR 7 , absence of perfect gold-standard 9 , biopsy gray zone 10 , spectrum effect 11 ) and their always cutting-edge statistical approach (obuschoswki 12 , DANA 13 , bayesian networks direct comparison 14 )
  • In addition to diagnostics, predicting risks of liver-related complications - including portal hypertension 15 and liver cancer 16 - in order to better identify the most appropriate response: FibroTest is the first non-invasive liver test to demonstrate a significant predictive value 17 .
  • FibroTest is the first test to have proved its effectiveness for themass screening for cirrhosis and liver disease indifferent populations at risk: in general population 18 , among diabetics 19 and hyperlipidemics 20 .


Quality at all costs is a core priority of BioPredictive: as a technology that has been validated by over 300 clinical trials FibroTest is an approved way of diagnosing the four most common liver diseases, including specific populations including : HIV co-infected 21 , transplanted patients 22 23 , vasculitis 24 , haemophilia 25 or primary biliary cirrhosis 26 but also for a large age spectrum, from children 27 to elderly patients 28 .

Quality and safety: BioPredictive's algorithms offer reliable diagnostic tools that give robust and reproducible results with an applicability of nearly 100% 29 .

Patients come first

Patients are at the heart of BioPredictive's concerns, and they are systematically taken into account throughout our work and our approach.

In 2002, we modernized the traditional results sheet to make it a reference document that would open up a genuine dialogue between patients and their physicians.

Finally, we aim to offer new tools, both to support users more effectively and to assist patients in the interpretation of their results.


  1. Poynard T, De Lédinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Lenaour G, Vaillant JC, Ratziu V, Charlotte F. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2012;36:5. abstract article
  2. Costa JM, Telehin D, Munteanu M, Kobryn T, Ngo Y, Thibault V, Joseph M, Ratziu V, Benhamou Y, Koz'ko V, Dubins'ka G, Poveda JD, Poynard T. HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2011;35:3. abstract article
  3. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005;4:None. abstract article
  4. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, De Lédinghen V. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:None. abstract article
  5. Thabut D, Naveau S, Charlotte F, Massard J, Ratziu V, Imbert-Bismut F, Cazals-Hatem D, Abella A, Messous D, Beuzen F, Munteanu M, Taieb J, Moreau R, Lebrec D, Poynard T. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J. Hepatol. 2006;44:6. abstract article
  6. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:9262. abstract article
  7. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:9055. abstract
  8. Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, Chaput JC. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991;100:5 Pt 1. abstract
  9. Poynard T, Ingiliz P, Elkrief L, Munteanu M, Lebray P, Morra R, Messous D, Bismut FI, Roulot D, Benhamou Y, Thabut D, Ratziu V. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS ONE 2008;3:12. abstract article
  10. Poynard T, Lenaour G, Vaillant JC, Capron F, Munteanu M, Eyraud D, Ngo Y, M'Kada H, Ratziu V, Hannoun L, Charlotte F. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin. Gastroenterol. Hepatol. 2012;10:6. abstract article
  11. Poynard T, Muntenau M, Morra R, Ngo Y, Imbert-Bismut F, Thabut D, Messous D, Massard J, Lebray P, Moussalli J, Benhamou Y, Ratziu V. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Gastroenterol. Clin. Biol. 2008;32:6 Suppl 1. abstract article
  12. Poynard T, Munteanu M, Ngo Y, Castéra L, Halfon P, Ratziu V, Imbert-Bismut F, Thabut D, Bourliere M, Cacoub P, Messous D, De Lédinghen V. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol. Clin. Biol. 2010;34:6-7. abstract article
  13. Poynard T, Halfon P, Castéra L, Munteanu M, Imbert-Bismut F, Ratziu V, Benhamou Y, Bourliere M, De Lédinghen V. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin. Chem. 2007;53:9. abstract article
  14. Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment. Pharmacol. Ther. 2016;43:1. abstract article
  15. Poynard T, Vergniol J, Ngo Y, Foucher J, Munteanu M, Merrouche W, Colombo M, Thibault V, Schiff E, Brass CA, Albrecht JK, Rudler M, Deckmyn O, Lebray P, Thabut D, Ratziu V, De Lédinghen V. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). J. Hepatol. 2014;60:4. abstract article
  16. Poynard T, Vergniol J, Ngo Y, Foucher J, Thibault V, Munteanu M, Merrouche W, Lebray P, Rudler M, Deckmyn O, Perazzo H, Thabut D, Ratziu V, De Lédinghen V. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®). J. Hepatol. 2014;61:5. abstract article
  17. Poynard T, Ngo Y, Perazzo H, Munteanu M, Lebray P, Moussalli J, Thabut D, Benhamou Y, Ratziu V. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) 2011;7:7. abstract
  18. Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, Norha P, Munteanu M, Drane F, Messous D, Bismut FI, Carrau JP, Massard J, Ratziu V, Giordanella JP. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010;10:None. abstract article
  19. Jacqueminet S, Lebray P, Morra R, Munteanu M, Devers L, Messous D, Bernard M, Hartemann-Heurtier A, Imbert-Bismut F, Ratziu V, Grimaldi A, Poynard T. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin. Gastroenterol. Hepatol. 2008;6:7. abstract article
  20. Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, Morra R, Imbert-Bismut F, Bruckert E, Poynard T. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment. Pharmacol. Ther. 2007;25:2. abstract article
  21. Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 2008;9:1. abstract article
  22. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, Imbertbismuth F, Lebray P, Pol S. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005;80:11. abstract
  23. Beckebaum S, Iacob S, Klein CG, Dechêne A, Varghese J, Baba HA, Sotiropoulos GC, Paul A, Gerken G, Cicinnati VR. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. Transplantation 2010;89:8. abstract article
  24. Sène D, Limal N, Messous D, Ghillani-Dalbin P, Charlotte F, Thiollière JM, Piette JC, Imbert-Bismut F, Halfon P, Poynard T, Cacoub P. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis. Clin. Biochem. 2006;39:7. abstract article
  25. Maor Y, Calès P, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Penaranda G, Bar-Meir S, Martinowitz U, Halfon P. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 2007;13:6. abstract article
  26. Friedrich-Rust M, Müller C, Winckler A, Kriener S, Herrmann E, Holtmeier J, Poynard T, Vogl TJ, Zeuzem S, Hammerstingl R, Sarrazin C. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. J. Clin. Gastroenterol. 2010;44:1. abstract article
  27. Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, Bernard O, Poynard T, Jacquemin E. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Gastroenterol. Clin. Biol. 2010;34:1. abstract article
  28. Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, Ratziu V, Poynard T. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am. J. Gastroenterol. 2006;101:6. abstract article
  29. Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Messous D, Castille JM, Housset C, Ratziu V, Imbert-Bismut F. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol 2011;11:None. abstract article